Watson A J, Stout R L, Whelton A
J Infect Dis. 1984 Nov;150(5):631-5. doi: 10.1093/infdis/150.5.631.
Using a healthy canine model, we evaluated the influence of renal physiological activity on the stability, intrarenal distribution, and clearance of aztreonam and compared the results with the concentrations of aztreonam that can be achieved in the scarred devitalized renal tissues of patients with end-stage kidney disease. Renal physiological activity significantly modulates the intrarenal distribution of aztreonam. During the production of maximally acid-concentrated urine, urinary aztreonam levels, clearance rates, and inner zone renal tissue concentrations are increased. Aztreonam concentrations in the parenchyma of severely diseased kidneys are significantly reduced in comparison with healthy tissues; nonetheless, the values are similar to concurrent serum drug levels, a result suggesting that treatment may provide adequate coverage for aztreonam-susceptible organisms.
我们使用健康犬模型评估了肾脏生理活性对氨曲南稳定性、肾内分布及清除率的影响，并将结果与终末期肾病患者瘢痕化无活力肾组织中可达到的氨曲南浓度进行比较。肾脏生理活性显著调节氨曲南的肾内分布。在产生最大酸度浓缩尿期间，尿中氨曲南水平、清除率及肾内带组织浓度均升高。与健康组织相比，严重病变肾脏实质中的氨曲南浓度显著降低；尽管如此，这些值与同期血清药物水平相似，这一结果表明治疗可能为氨曲南敏感菌提供足够的覆盖范围。
